Safety information on QT-interval prolongation: Comparison of European Union and United States drug labeling

Drug Discovery Today

Volumn 19, Issue 9, 2014, Pages 1294-1297

  Warnier, Miriam J ^a,b   Holtkamp, Frank A ^c,d   Rutten, Frans H ^b   Hoes, Arno W ^b   De Boer, Anthonius ^a   Mol, Peter G M ^c,d   De Bruin, Marie L ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; NEW DRUG;

CLINICAL EVALUATION; COMPARATIVE STUDY; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG EFFECT; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN UNION; HEALTH CARE PERSONNEL; HUMAN; PATIENT SAFETY; QT INTERVAL; QT PROLONGATION; REVIEW; SEMANTICS; SYSTEMATIC REVIEW; UNITED STATES; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; LONG QT SYNDROME; STATISTICS AND NUMERICAL DATA;

DRUG LABELING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPEAN UNION; HUMANS; LONG QT SYNDROME; UNITED STATES;

EID: 84907846236     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.06.017     Document Type: Short Survey

References (10)

1. L. Cubeddu QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs Am. J. Ther. 10 2003 452 457
2. D. Kramer, and P. Zimetbaum Long-QT syndrome Cardiol. Rev. 19 2011 217 225
3. N. Stockbridge Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf. 36 2013 167 182
4. P.G. Mol A decade of safety-related regulatory action in The Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009 Drug Saf. 33 2010 463 474
5. A.S. Kesselheim Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs BMJ Qual. Saf. 22 2013 727 734
6. P. Bahri, and M. Harrison-Woolrych Focusing on risk communication about medicines: why now? Drug Saf. 35 2012 971 975
7. M.J. Warnier Quality of drug label information on QT interval prolongation Int. J. Risk Saf. Med. 26 2014 89 98
8. R. Shimazawa, and M. Ikeda Safety information in drug labeling: a comparison of the USA, the UK, and Japan Pharmacoepidemiol. Drug Saf. 22 2013 306 318
9. S.M. Al-Khatib A survey of health care practitioners' knowledge of the QT interval J. Gen. Intern. Med. 20 2005 392 396
10. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1977 159 174